| アブストラクト | OBJECTIVES: Pulmonary hypertension (PH) associated with lung disease (Group 3 PH) is a serious complication that negatively impacts patient outcomes. This study aimed to assess the epidemiology and disease burden of Group 3 PH in the UK, focusing on interstitial lung disease (ILD-PH). DESIGN: Retrospective cohort study. SETTING: Electronic medical records from the Clinical Practice Research Datalink Aurum, linked to Hospital Episode Statistics. PARTICIPANTS: 6690 incident cases of Group 3 PH, including 1561 ILD-PH cases, were identified from a sample of approximately 33 million individuals between January 2017 and December 2019. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcomes included prevalence and incidence of Group 3 PH and ILD-PH. Secondary outcomes included patient characteristics, overall survival, hospitalisations, outpatient visits and healthcare costs. RESULTS: Over the 3-year period, prevalence and annual incidence were 139/million (95% CI 134 to 142) and 73/million/year (95% CI 70 to 76) for Group 3 PH and 36/million (95% CI 33 to 37.3) and 17/million/year (95% CI 16 to 19) for ILD-PH. Median overall survival was 19.3 (95% CI 17.77 to 20.8) for Group 3 PH and 15.1 months (95% CI 12.66 to 18.2) for ILD-PH. Following a PH diagnosis, all-cause inpatient visits increased by 33.6% from baseline. The all-cause annual hospitalisation rate was 1.63 (95% CI 1.6 to 1.65) for Group 3 PH and 1.36 (95% CI 1.31 to 1.4) for ILD-PH, with about half linked to PH diagnosis. Pulmonologists were the most consulted specialists, averaging 1.78 (95% CI 1.76 to 1.81) and 2.31 (95% CI 2.25 to 2.37) visits per patient per year for Group 3 PH and ILD-PH, respectively. Annual per-patient costs were pound7761 (95% CI 7759 to 7762) for Group 3 PH and pound7170 (95% CI 7167.17 to 7173.69) for ILD-PH. CONCLUSION: Incidence and prevalence of Group 3 PH in the UK are consistent with other European countries. Patients had poor survival, with PH associated with half of hospital admissions, highlighting the negative impact of PH in chronic lung disease. |
|---|
| ジャーナル名 | BMJ open |
|---|
| Pubmed追加日 | 2026/2/28 |
|---|
| 投稿者 | Kiely, David G; Wort, S John; Funes, Diego; Fernandez Delgado, Miriam; Petrica, Nicoleta; Proenca, Catia; Bacchini Jeanneret, Gabriela |
|---|
| 組織名 | Sheffield Pulmonary Vascular Disease Unit, Sheffield Teaching Hospitals NHS;Foundation Trust, Sheffield, UK.;Department of Infection, Immunity and Cardiovascular Disease, The University of;Sheffield, Sheffield, UK.;Department of Pulmonary Hypertension, Royal Brompton Hospital, London, UK.;Ferrer International SA, Barcelona, Spain dfunes@ferrer.com.;Ferrer International SA, Barcelona, Spain.;Alira Health, Paris, France.;Alira Health AG, Basel, Switzerland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41760140/ |
|---|
